• 1. Department of General Surgery of The Third People’s Hospital,Chengdu 610031 China ; 2. West China Hospital of Sichuan University ,610041 Chengdu China;3. Breast Disease Treatment Center of West China Hospital of Sichuan University, Chengdu 610041, China;
LUO Jing, Email: luojingzzy@yahoo.com.cn
Export PDF Favorites Scan Get Citation

Objective  To evaluate the effect of neoadjuvant chemotherapy (NAC) on breast conserving surgery and the outcomes of treatment for women with operable breast cancer.
Methods  We searched The Cochrane Library (Issue 1, 2007), CENTRAL (1970 to 2007), PUBMED (1978 to March 2007), CBM (1978 to 2006), CNKI (1994 to 2007), CMCC (1994 to May 2007) and other relevant databases and journals. We identified randomized controlled trials (RCTs) comparing NAC plus breast conserving therapy (BCT) or mastectomy versus BCT or mastectomy plus postoperative chemotherapy in women with operable breast cancer. Two reviewers independently assessed trial quality and extracted data. Meta-analyses were performed for homogenous studies by using The Cochrane Collaboration’s RevMan 4.2.10.
Results  Three eligible studies involving 2 391 women were included. The median follow-up in the studies ranged from 17 to 137 months. The methodological quality of the three RCTs was high. Meta-analyses showed that NAC had no significant effect on overall survival (OS) (RR 0.99, 95%CI 0.92 to 1.07), disease-free survival (RR 1.04, 95%CI 0.94 to 1.15) and ipsilateral breast cancer recurrence (RR 1.34, 95%CI 0.84 to 2.13). Two RCTs revealed that NAC significantly increased the rate of BCT in operable breast cancer patients, but the other RCT reported similar rates of BCT in both groups. One RCT indicated that NAC did not increase the incidence of surgery-related local complications.
Conclusions  NAC is safe for the treatment of women with operable breast cancer, which may increase the rate of BCT and help to evaluate chemosensitivity. There is insufficient evidence to assess the effect of NAC on conserving surgery procedure and survival rate in operable BCT patients. More large-scale RCTs are needed to define further the role of NAC in the treatment of operable breast cancer patients.

Citation: LUO Jing,LI Youping,WU Taixiang,LV Qing. Breast Conserving Therapy after Neoadjuvant Chemotherapy in Operable Breast Cancer Patients: A Systematic Review. Chinese Journal of Evidence-Based Medicine, 2008, 08(7): 551-557. doi: 10.7507/1672-2531.20080126 Copy

  • Previous Article

    Efficacy and Safety of Levoamlodipine Besylate for Essential Hypertension: A Systematic Review
  • Next Article

    The Effect of Using “Education Prescription” in the Evidence Retrieval Teaching Practice